Nektar Therapeutics (NKTR)

Nektar Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	90.12	92.06	101.91	152.92	114.62
Revenue Growth (YoY)	-2.10%	-9.67%	-33.36%	33.41%	-90.40%
Cost of Revenue	33.77	21.64	24.9	19.48	21.37
Gross Profit	56.35	70.42	77.01	133.44	93.24
Selling, General & Admin	77.42	92.33	122.84	104.68	98.71
Research & Development	114.16	218.32	400.27	408.68	434.57
Other Operating Expenses	128.46	135.93	0	45.19	0
Operating Expenses	320.04	446.59	523.11	558.55	533.28
Operating Income	-263.68	-376.17	-446.1	-425.11	-440.04
Interest Expense / Income	25.33	28.91	47.31	37.12	46.35
Other Expense / Income	-12.76	-40.09	29.86	-18.28	-46.34
Pretax Income	-276.26	-364.98	-523.28	-443.95	-440.05
Income Tax	-0.2	3.22	0.56	0.49	0.61
Net Income	-276.06	-368.2	-523.84	-444.44	-440.67
Shares Outstanding (Basic)	190	187	183	179	175
Shares Outstanding (Diluted)	190	187	183	179	175
Shares Change	1.53%	2.09%	2.64%	2.05%	-2.85%
EPS (Basic)	-1.45	-1.97	-2.86	-2.49	-2.52
EPS (Diluted)	-1.45	-1.97	-2.86	-2.49	-2.52
Free Cash Flow	-192.23	-296.49	-427.65	-320.55	-354.97
Free Cash Flow Per Share	-1.01	-1.58	-2.33	-1.79	-2.03
Gross Margin	62.53%	76.50%	75.57%	87.26%	81.35%
Operating Margin	-292.59%	-408.63%	-437.76%	-278.00%	-383.92%
Profit Margin	-306.31%	-399.98%	-514.03%	-290.65%	-384.47%
Free Cash Flow Margin	-213.30%	-322.08%	-419.65%	-209.62%	-309.70%
EBITDA	-243.11	-323.04	-461.82	-392.65	-380.54
EBITDA Margin	-269.75%	-350.92%	-453.18%	-256.77%	-332.01%
Depreciation & Amortization	7.82	13.03	14.15	14.18	13.16
EBIT	-250.92	-336.07	-475.97	-406.83	-393.7
EBIT Margin	-278.42%	-365.08%	-467.06%	-266.05%	-343.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).